Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Fish and Richardson
McKinsey
Deloitte
Chinese Patent Office
Healthtrust
Queensland Health
Medtronic
Cipla

Generated: November 17, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,544,364

« Back to Dashboard

Summary for Patent: 7,544,364
Title:Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Abstract:Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
Inventor(s): Judice; J. Kevin (El Granada, CA), Shaw; Jeng-Pyng (Saratoga, CA), Mu; YongQi (Los Altos, CA), Conner; Michael W. (Half Moon Bay, CA), Pace; John L. (San Anselmo, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:11/410,597
Patent Claims: 1. A pharmaceutical composition comprising: (a) a cyclodextrin; and (b) a glycopeptide antibiotic or a pharmaceutically acceptable salt thereof; wherein the glycopeptide antibiotic has the formula: ##STR00008## Wherein R.sup.20 is a lipid substituent containing from 10 to 40 carbon atoms, and optionally containing heteroatoms selected from halo, oxygen, nitrogen, sulfur and phosphorous; and wherein R.sup.19 is hydrogen, and R.sup.5 is a substituent of the formula: --CH.sub.2--NH--R.sup.a--P(O)(OH).sub.2 wherein R.sup.a is alkylene.

2. The pharmaceutical composition of claim 1, wherein the cyclodextrin is hydroxypropyl-.beta.-cyclodextrin.

3. The pharmaceutical composition of claim 1, wherein the cyclodextrin is sulfobutyl ether .beta.-cyclodextrin.

4. The pharmaceutical composition of claim 1, wherein the composition is a lyophilized powder.

5. The pharmaceutical composition of claim 1, wherein the cyclodextrin comprises about 1 to 40 weight percent of the composition.

6. The pharmaceutical composition of claim 1, wherein the glycopeptide antibiotic is in the form of a pharmaceutically acceptable salt.

7. The pharmaceutical composition of claim 1, wherein the glycopeptide antibiotic is in the form of a hydrochloride salt.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Dow
Healthtrust
Johnson and Johnson
Daiichi Sankyo
Teva
Mallinckrodt
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.